Previous 10 |
BURLINGAME, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered ® monoclonal antibodies focused on chimeric antigen receptor T (CAR-T) cell therapy optimiza...
Gilead Sciences ( GILD -1.7% ) unit Kite Pharma will collaborate with Humanigen ( OTCQB:HGEN +8.7% ) on a Phase 1/2 clinical trial evaluating the combination of CAR T therapy Yescarta (axicabtagene ciloleucel) and lenzilumab in patients with relapsed/refractory diffuse large B-cell lym...
SANTA MONICA, Calif. and BURLINGAME, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Kite, a Gilead Company (Nasdaq: GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal ant...
-- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 -- Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclon...
Severe neurotoxicity (NT) is a negative prognostic factor for overall survival with chimeric antigen receptor T-cell (CAR-T) therapy Prolonged exposure of corticosteroids for severe NT may negatively in fl uence overall survival GM-CSF neutralization identified as a pote...
Study Demonstrates that Dosing with Ifabotuzumab Results in Rapid, Specific and Reproducible Targeting of the Tumor Microenvironment in Patients with Glioblastoma Multiforme (GBM) Imaging Changes Suggest Modulation of the Tumor Vasculature by Ifabotuzumab without Normal Tissue ...
Enhanced anti-tumor activity, improved overall survival, and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralization Lenzilumab (an anti-GM-CSF monoclonal antibody) used in combination with CAR-T therapy prevents cytokine release syndrome,...
First ever demonstration that the spectrum of toxicities seen in CAR-T clinical trials can be effectively prevented in vivo Enhanced anti-tumor activity, improved overall survival, and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralizatio...
Enhanced anti-tumor activity, improved overall survival, and an exponential increase in CAR-T cell proliferation was observed with GM-CSF neutralization Lenzilumab (an anti-GM-CSF antibody) used in combination with CAR-T significantly reduces neuro-inflammation, prevents cytokine r...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...